發(fā)布時間：2018-08-19 11:59

【摘要】：目的:系統(tǒng)評價托瑞米芬對比他莫昔芬治療乳腺癌的安全性,為臨床提供循證參考。方法:計算機檢索Medline、PubMed、EMBase、Cochrane圖書館、相關(guān)期刊論文、中國生物醫(yī)學文獻數(shù)據(jù)庫、中文科技期刊數(shù)據(jù)庫和萬方庫數(shù)據(jù)庫,收集托瑞米芬對比他莫昔芬治療乳腺癌安全性的隨機對照研究(RCT)及隊列研究,提取資料并評價質(zhì)量后,采用Rev Man 5.0統(tǒng)計軟件進行Meta分析。結(jié)果:共納入10項RCT和9項回顧性隊列研究,合計9 182例患者。Meta分析結(jié)果顯示,托瑞米芬組患者總體藥品不良反應(yīng)發(fā)生率與他莫昔芬組比較差異無統(tǒng)計學意義[RR=0.88,95%CI(0.73,1.06),P=0.18];按托瑞米芬劑量進行亞組分析顯示,常規(guī)劑量和高劑量托瑞米芬組患者與他莫昔芬組比較差異均無統(tǒng)計學意義。托瑞米芬組患者嚴重不良反應(yīng)發(fā)生率與他莫昔芬組比較差異無統(tǒng)計學意義[OR=0.60,95%CI(0.23,1.52),P=0.28]。常規(guī)劑量托瑞米芬組患者血栓事件發(fā)生情況[OR=0.77,95%CI(0.60,0.98),P=0.03]、消化系統(tǒng)不良反應(yīng)發(fā)生情況[OR=0.81,95%CI(0.70,0.94),P=0.006]、月經(jīng)不規(guī)則的發(fā)生率[OR=0.61,95%CI(0.39,0.94),P=0.03]、出現(xiàn)發(fā)熱伴/不伴寒戰(zhàn)情況[OR=0.56,95%CI(0.34,0.92),P=0.02]等方面均優(yōu)于他莫昔芬組,差異均有統(tǒng)計學意義。高劑量托瑞米芬組患者對比他莫昔芬的各類不良反應(yīng)發(fā)生情況,差異均無統(tǒng)計學意義。結(jié)論:相較于他莫昔芬,常規(guī)劑量托瑞米芬治療乳腺癌時在消化道不良反應(yīng)、血栓事件、月經(jīng)不規(guī)則、發(fā)熱伴/不伴寒戰(zhàn)等藥品不良反應(yīng)方面安全性較好。
[Abstract]:Objective: to systematically evaluate the safety of tamoxifen in the treatment of breast cancer and provide evidence-based reference for clinical practice. Methods: a computer-based search of Medline PubMeden was conducted in the Library of Cochrane, the full text Database of Chinese Journals, the Database of Chinese Biomedical Literature, the Database of Chinese Sci-tech Journals and the Database of Wanfang Library. A randomized controlled study (RCT) and a cohort study of the safety of tamoxifen in the treatment of breast cancer were collected. The data were extracted and the quality was evaluated. The Meta analysis was performed with Rev Man 5.0 statistical software. Results: a total of 10 RCT and 9 retrospective cohort studies were included. There was no significant difference in the overall incidence of adverse drug reactions between the tolemiphene group and tamoxifen group [RRN 0.88 + 95 CI (0.73 鹵1.06)], and the subgroup analysis according to the dose of Toremifene showed that there was no significant difference in the incidence of adverse drug reactions (ADR) between the Toremifen group and the tamoxifen group. There was no significant difference between conventional and high dose tolemiphene groups and tamoxifen groups. There was no significant difference in the incidence of severe adverse reactions between Toremifen group and tamoxifen group. The incidence of thrombotic events in patients with conventional dose of Toremifen [ORO 0.7795 95 CI (0.600.98) P0. 03], adverse reactions of digestive system [ORP 0. 81 + 95 CI (0. 70 0. 94) P 0. 006], the incidence of irregular menstruation [OR0. 619 95 CI (0. 399 0. 94) P0. 03], fever with / without chills [OR0. 56% 95 CI (0. 34 0. 92) P0.02] were better than those in tamoxifen group. The difference was statistically significant. There was no significant difference in the incidence of adverse reactions of high dose toremifen group compared with that of tamoxifen group. Conclusion: compared with tamoxifen, conventional dose of Toremifen has better safety in adverse reactions of digestive tract, thrombus, irregular menstruation, fever with or without shivering and other adverse drug reactions in the treatment of breast cancer.
【作者單位】： 成都市第三人民醫(yī)院西藥科;
【基金】：四川省預(yù)防醫(yī)學會藥物應(yīng)用安全科研(孵化)項目(No.川預(yù)學[2013]70號)
【分類號】：R737.9

【相似文獻】

相關(guān)期刊論文 前10條

1 孫學民;童曉文;;托瑞米芬的臨床應(yīng)用及研究進展[J];中國現(xiàn)代應(yīng)用藥學;2006年S3期

2 李鵬;馬艷嬌;曹劍;郜冬雪;;托瑞米芬的研究進展[J];黑龍江八一農(nóng)墾大學學報;2009年05期

3 孔祥林;;托瑞米芬的藥理及臨床[J];國外醫(yī)藥.合成藥.生化藥.制劑分冊;1992年01期

4 安東建;柴琴;田垣;蘇天海;湯效;謝熠;;大劑量托瑞米芬逆轉(zhuǎn)肺癌多藥耐藥及化療增敏的臨床研究[J];中國腫瘤臨床與康復(fù);2009年01期

5 Harvey HA;Kimura M;Hajba A.;李文萍;王頎;;托瑞米芬的安全性評估[J];中華乳腺病雜志(電子版);2007年01期

6 張雪艷;李強;劉忠令;韓一平;;托瑞米芬與化療藥物協(xié)同抑制肺癌A549細胞生長[J];中國癌癥雜志;2002年05期

7 張建龍;托瑞米芬在腫瘤輔助化療中的研究進展[J];嶺南現(xiàn)代臨床外科;2001年03期

8 喬良;孟慶榆;劉淑杰;代春梅;;祛瘀散結(jié)膠囊聯(lián)合托瑞米芬治療乳腺增生病的臨床研究[J];中國醫(yī)學創(chuàng)新;2011年03期

9 孔祥林;于盛海;徐大江;;抗雌激素類抗腫瘤藥托瑞米芬的研究進展[J];國外醫(yī)學.婦產(chǎn)科學分冊;1992年04期

10 周彩存,張捷,鄭迪,呂梅君,魯冰,徐建芳;托瑞米芬聯(lián)合長春地辛和順鉑化療方案治療不能手術(shù)切除的非小細胞肺癌[J];中華結(jié)核和呼吸雜志;2004年08期

相關(guān)會議論文 前3條

1 張紹芬;夏賢;朱慧庭;劉e，

本文編號：2191591